Crossref

1. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases

- Trinath Chowdhury

- Gourisankar Roymahapatra

- Santi M. Mandal

2. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study

- K. Abraham Peele

- Chandrasai Potla Durthi

- T. Srihansa

- S. Krupanidhi

- Vijaya Sai Ayyagari

- D. John Babu

- M. Indira

- A. Ranganadha Reddy

- T.C. Venkateswarulu

3. SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development

- Guilherme Antonio de Souza Silva

- Suéllen Pedrosa da Silva

- Marcos Aurélio Santos da Costa

- Abdênego Rodrigues da Silva

- Robson Raion de Vasconcelos Alves

- Fernanda das Chagas Ângelo Mendes Tenório

- Alanne Rayssa da Silva Melo

- Antonio Carlos de Freitas

- Cristiane Moutinho Lagos de Melo

4. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report

- Ling Ning

- Lei Liu

- Wenyuan Li

- Hongtao Liu

- Jizhou Wang

- Ziqin Yao

- Shengyu Zhang

- Desheng Zhao

- Björn Nashan

- Aizong Shen

- Lianxin Liu

- Lei Li

5. Classification, structure and mechanism of antiviral polysaccharides derived from edible and medicinal fungus

- Yuxi Guo

- Xuefeng Chen

- Pin Gong

6. Integrating LC–MS/MS and In Silico Methods to Uncover Bioactive Compounds with Lipase Inhibitory Potential in the Antarctic Moss Warnstorfia fontinaliopsis

- Hirotake Yamaguchi

- Ryoichi Yamada

- Kristina Lama

- Ui Joung Youn

- Jun Hyuck Lee

- Tae-Jin Oh

7. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach

- Phulen Sarma

- Manisha Prajapat

- Pramod Avti

- Hardeep Kaur

- Subodh Kumar

- Bikash Medhi

8. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19

- Nils von Hentig

9. Available Antiretrovirals in the Treatment and Pre-Exposure Prophylaxis of SARS-CoV-2: Quo Vadis?

- Miguel Alpalhão

- Paulo Filipe

10. Natural Products as Anti-COVID-19 Agents: An In Silico Study

- Chandan Sarkar

- Sarmin Jamaddar

- Milon Mondal

- Abul Bashar Ripon Khalipha

- Muhammad Torequl Islam

- Mohammad S. Mubarak

11. Targeting COVID-19 pandemic: in silico evaluation of 2-hydroxy-1, 2-diphenylethanone N(4)-methyl-N(4)-phenylthiosemicarbazone as a potential inhibitor of SARS-CoV-2

- Rajan Jeevana

- Abu Pilakkaveettil Kavitha

- Thoppilan G. Abi

- Pookkottu K. Sajith

- Jibin K. Varughese

- Kuttamath Kunniyur Aravindakshan

12. Computational Approaches for Lead Discovery against SARS-CoV-2 3C-Like Protease: Virtual Screening and Molecular Dynamics Studies

- Mohammad Kalim Ahmad Khan

- Feras Almarshad

13. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

- Yu Wai Chen

- Chin-Pang Bennu Yiu

- Kwok-Yin Wong

14. Finding a prospective dual-target drug for the treatment of coronavirus disease by theoretical study

- Karim Mahnam

- Zahra Ghobadi

15. Drug Safety Issues in Therapy COVID-19

- D. G. Levitova

- S. A. Gracheva

- A. S. Samoylov

- U. D. Udalov

- E. A. Praskurnichiy

- O. V. Parinov

16. Safety perspectives on presently considered drugs for the treatment of COVID‐19

- Sophie L. Penman

- Robyn T. Kiy

- Rebecca L. Jensen

- Christopher Beoku‐Betts

- Ana Alfirevic

- David Back

- Saye H. Khoo

- Andrew Owen

- Munir Pirmohamed

- B. Kevin Park

- Xiaoli Meng

- Christopher E. Goldring

- Amy E. Chadwick

17. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

- Michele Costanzo

- Maria Anna Rachele De Giglio

- Giovanni Nicola Roviello

18. Investigating the mechanisms of ethanol-induced disruption of COVID-19 lipid bilayers through molecular dynamics simulations

- Azadeh Kordzadeh

- Ahmad Ramazani SA

19.

20. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment

- Nathan Ford

- Marco Vitoria

- Ajay Rangaraj

- Susan L Norris

- Alexandra Calmy

- Meg Doherty

21. RETRACTED ARTICLE: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

- Yasemin Cag

- Sacit Icten

- Burcu Isik-Goren

- Naciye Betul Baysal

- Begum Bektas

- Ece Selvi

- Pinar Ergen

- Ozlem Aydin

- Ayse Canan Ucisik

- Fatma Yilmaz-Karadag

- Hulya Caskurlu

- Tulin Akarsu-Ayazoglu

- Hasan Kocoglu

- Sinan Uzman

- Muge Nural-Pamukcu

- Ferhat Arslan

- Gurhan Bas

- Mahmut Tayyar Kalcioglu

- Haluk Vahaboglu

22. Potential Pathogenicity Determinants Identified from Structural Proteomics of SARS-CoV and SARS-CoV-2

- Erica T Prates

- Michael R Garvin

- Mirko Pavicic

- Piet Jones

- Manesh Shah

- Omar Demerdash

- B Kirtley Amos

- Armin Geiger

- Daniel Jacobson

- Malik Harmit

23. Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery

- Supriya Roy

- Suneela Dhaneshwar

- Bhavya Bhasin

24. An Overview of COVID-19: Focus on Pharmacological Aspect

- Nandhini Saravanabavan

- Padmavathi Shanmuganathan

- Manimekalai Kumarappan

- Kartik J Salwe

- Barathane Datchanamurthy

- Johan Pandian

- R Sudar Codi

- Vimala Ananthy

- Kamalasundar Thanuskodi

- Uma Narayanamurthy

25. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective

- Simone Perazzolo

- Linxi Zhu

- Weixian Lin

- Alexander Nguyen

- Rodney J.Y. Ho

26. Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction

- Ankita Saha

- Shweta Choudhary

- Priyanshu Walia

- Pravindra Kumar

- Shailly Tomar

27. Potential repurposed SARS-CoV-2 (COVID-19) infection drugs

- Gamal El-Din A. Abuo-Rahma

- Mamdouh F. A. Mohamed

- Tarek S. Ibrahim

- Mai E. Shoman

- Ebtihal Samir

- Rehab M. Abd El-Baky

28. A multiple peptides vaccine against COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the immunoinformatics approach

- Sahar Obi Abd Albagi

- Mosab Yahya Al-Nour

- Mustafa Elhag

- Asaad Tageldein Idris Abdelihalim

- Esraa Musa Haroun

- Mohammed Elmujtba Adam Essa

- Mustafa Abubaker

- Hemchandra Deka

- Arabinda Ghosh

- Mohammed A. Hassan

29. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study

- Nouman Rasool

- Ammara Akhtar

- Waqar Hussain

30. FDA recommended potent drugs against COVID-19: Insight through molecular docking

- Khushbu Gumber

- Pomila

31. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses

- Nakarin Suwannarach

- Jaturong Kumla

- Kanaporn Sujarit

- Thanawat Pattananandecha

- Chalermpong Saenjum

- Saisamorn Lumyong

32. The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course

- N. V. Bobkova

33. COVID-19 and HIV/AIDS in a cohort study in Sao Paulo, Brazil: outcomes and disparities by race and schooling

- S. Q. Rocha

- V. I. Avelino-Silva

- M. V. Tancredi

- L. F. Jamal

- P. R. A. Ferreira

- A. Tayra

- P. M. Ferreira

- T. Carvalhanas

- C. S. B. Domingues

- R. A. Souza

- M. C. Gianna

- A. O. Kalichman

- O. H. M. Leite

- T. N. L. Souza

- D. A. Gomes e Costa

- J. J. D. Furtado

- A. F. Costa

34. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

- Purwati

- Andang Miatmoko

- Nasronudin

- Eryk Hendrianto

- Deya Karsari

- Aristika Dinaryanti

- Nora Ertanti

- Igo Syaiful Ihsan

- Disca Sandyakala Purnama

- Tri Pudy Asmarawati

- Erika Marfiani

- Yulistiani

- Alfian Nur Rosyid

- Prastuti Asta Wulaningrum

- Herley Windo Setiawan

- Imam Siswanto

- Ni Nyoman Tri Puspaningsih

- Mrinmoy Sanyal

35. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India

- Tarun Bhatnagar

- Manoj V. Murhekar

- Manish Soneja

- Nivedita Gupta

- Sidhartha Giri

- Naveet Wig

- Raman Gangakhedkar

36. Therapeutic opportunities of edible antiviral plants for COVID-19

- Bhoomika Patel

- Supriya Sharma

- Nisha Nair

- Jaseela Majeed

- Ramesh K. Goyal

- Mahaveer Dhobi

37. Current pharmacological treatments for COVID‐19: What's next?

- Cristina Scavone

- Simona Brusco

- Michele Bertini

- Liberata Sportiello

- Concetta Rafaniello

- Alice Zoccoli

- Liberato Berrino

- Giorgio Racagni

- Francesco Rossi

- Annalisa Capuano

38. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock

- Dipti Mothay

- K. V. Ramesh

39. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design

- Maria Bzówka

- Karolina Mitusińska

- Agata Raczyńska

- Aleksandra Samol

- Jack A. Tuszyński

- Artur Góra

40. COVID-19: a wreak havoc across the globe

- Heena Rehman

- Md Iftekhar Ahmad

41. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (Mpro) of SARS-CoV-2

- Arabinda Ghosh

- Monoswi Chakraborty

- Anshuman Chandra

- Mohamad Parvez Alam

42. COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach

- Soha R Abd El Hadi

- Esmat E Zien El-Deen

- Mostafa M Bahaa

- Abdelfattah A Sadakah

- Heba A Yassin

43. In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia(giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach

- Papia Chowdhury

44. Screening of potential anti-HIV compounds from Achyranthes aspera extracts for SARS-CoV-2: An insight from molecular docking study

- Tanmoy Dutta

- Sajal Ghorai

- Abdul Ashik Khan

- Nabajyoti Baildya

- Narendra Nath Ghosh

45. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study

- Vanderlan Nogueira Holanda

- Elton Marlon de Araújo Lima

- Welson Vicente da Silva

- Rafael Trindade Maia

- Rafael de Lima Medeiros

- Arabinda Ghosh

- Vera Lúcia de Menezes Lima

- Regina Celia Bressan Queiroz de Figueiredo

46. Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19

- Ekta Shirbhate

- Preeti Patel

- Vijay K Patel

- Ravichandran Veerasamy

- Prabodh C Sharma

- Barij N Sinha

- Harish Rajak

47. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

- Yu Wai Chen

- Chin-Pang Bennu Yiu

- Kwok-Yin Wong

48. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening

- Cristina Adriana Dehelean

- Voichita Lazureanu

- Dorina Coricovac

- Marius Mioc

- Roxana Oancea

- Iasmina Marcovici

- Iulia Pinzaru

- Codruta Soica

- Aristidis M. Tsatsakis

- Octavian Cretu

49. In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19

- Peter Ifeoluwa Adegbola

- Olumide Samuel Fadahunsi

- Aanuoluwa Eunice Adegbola

- Banjo Semire

50. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

- Surjeet Verma

- Danielle Twilley

- Tenille Esmear

- Carel B. Oosthuizen

- Anna-Mari Reid

- Marizé Nel

- Namrita Lall

51. In Silico Investigation of the SARS CoV2 Protease with Thymoquinone, the Major Constituent of Nigella Sativa

- Youness Kadil

- Mohammed Mouhcine

- Houda Filali

52. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

- Bo Ram Beck

- Bonggun Shin

- Yoonjung Choi

- Sungsoo Park

- Keunsoo Kang

53. Biophysics of SARS-CoV-2 spike protein’s receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights

- Fernando Luís Barroso da Silva

- Karen Paco

- Aatto Laaksonen

- Animesh Ray

54. Therapeutic approaches to coronavirus infection according to “One Health” concept

- Giacomo Rossi

- Livio Galosi

- Alessandra Gavazza

- Matteo Cerquetella

- Sara Mangiaterra

55.

56. A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

- Sumel Ashique

- Navjot K. Sandhu

- Sk. Niyamul Haque

- Kartick Koley

57. Identification of Anti-SARS-CoV-2 Compounds from Food Using QSAR-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Analysis

- Magdi E. A. Zaki

- Sami A. Al-Hussain

- Vijay H. Masand

- Siddhartha Akasapu

- Sumit O. Bajaj

- Nahed N. E. El-Sayed

- Arabinda Ghosh

- Israa Lewaa